About talq ueta mab
BCMA×GPRC5D bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after prior treatments.
Usual adult dose
Given under the skin using a step-up schedule, then weekly or every two weeks; specialist-directed dosing.
Common side effects
- Cytokine release syndrome
- Infections
- Taste changes
- Skin or nail problems
Important warnings
- Can cause serious cytokine release syndrome and neurological toxicity.
- Treatment can increase infection risk and reduce blood-cell counts.
- Only trained healthcare professionals should administer and monitor treatment.
- May cause severe skin reactions or mouth problems.
Pregnancy
May harm an unborn baby; effective contraception is recommended during treatment and for three months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months afterward.
Interactions
- Talquetamab may alter how some CYP enzyme-processed medicines work; review medicines with the care team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.